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Brazil is one of the 22  countries that concentrates 80% of global tuberculosis cases concomi-
tantly to a  large number of hepatitis C carriers and some epidemiological risk scenarios
are  coincident for both diseases. We  analyzed tuberculosis cases that occurred during -
interferon-based therapy for hepatitis C in reference centers in Brazil between 2001 and 2012
and  reviewed their medical records. Eighteen tuberculosis cases were observed in patients
submitted  to hepatitis C -interferon-based therapy. All patients were human immuno-
deficiency virus-negative. Nine patients (50%) had extra-pulmonary tuberculosis; 15  (83%)
showed significant liver fibrosis. Hepatitis C treatment was discontinued in 12 patients (67%)
due  to  tuberculosis reactivation and six (33%) had sustained virological response. The major-
ity of patients had a  favorable outcome but one died. Considering the  evidences of -IFN
interference over the containment of Mycobacterium tuberculosis,  the immune impairment
of cirrhotic patients, the  increase of tuberculosis case reports during hepatitis C treatment
with  atypical and severe presentations and the  negative impact on sustained virological
response, we think these are strong arguments for latent tuberculosis infection screening
before starting -interferon-based therapy for any indication and even to consider IFN-free
regimens against hepatitis C when a  patient tests positive for latent tuberculosis infection.
©  2016 Elsevier Editora Ltda. This is an  open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Tuberculosis (Tb) is  an air-borne infectious disease caused
by the Mycobacterium tuberculosis, considered priority for
surveillance and treatment by the World  Health Organization
because of its high incidence and mortality rates, especially in
countries with socio-economic and sanitary issues.
Brazil is one of the  22 countries in the world that concen-
trate 80% of global Tb cases, ranking 16th in absolute number
of cases (71,123 cases in 2013) and 22nd in incidence rate (35.4
cases/100,000 inhabitants). Most of the reported cases occur
among men  in  the age group from 40 to 59 years, with pul-
monary presentation (86%).1
Some groups are more  susceptible to Tb than the gen-
eral population, such as  patients living with the human
immunodeficiency virus/acquired immunodeficiency syn-
drome (HIV/Aids), patients under immunosuppressive or
immunobiological therapy as  with rheumatic, inflammatory
bowel disease, and also in  diabetis, chronic kidney disease,
and solid organ transplanted patients.
The treatment of Tb with rifampicin, isoniazid and pyraz-
inamide was adopted in Brazil until 2009. From 2010 on, the
drug regimen containing rifampicin, isoniazid, pyrazinamide,
and ethambutol was adopted. Alternative therapy is recom-
mended for patients with liver diseases or aminotransferases
abnormalities, including streptomycin, ofloxacin, and etham-
butol (SOE).2
The standard therapy for chronic hepatitis C has changed
significantly during the years. Initially patients were treated
with conventional interferon. When pegylated interferon
became available patients had a  more  convenient and effec-
tive therapy with a  duration of 24–48 weeks depending on
the hepatitis C virus (HCV) genotype and fibrosis stage. In
special situations such as  end-stage renal disease (ESRD) iso-
lated IFN was recommended due to  the high risk of hemolytic
anemia induced by ribavirin. This association of drugs could
also lead to a relative immunosuppression. Nowadays several
direct acting antiviral drugs (DAA) are available with high cure
rates, shorter duration of treatment, and fewer adverse events.
Even in this new era of CHC treatment, IFN will still be used
in some situations such as genotype 3 infection and rescue
therapy for non-responders.3
Hepatitis C patients treated with -interferon (-IFN) and
ribavirin are not yet characterized as  a more  susceptible group
for developing Tb, although it is already known that there is
an increase on hepatitis C prevalence among Tb patients when
compared to the general population.4 Indeed, some epidemio-
logical risk scenarios are coincident for both diseases, such as
incarceration, homelessness, and drug addiction.1 Other risk
factors for Tb such as  undernourishment and relative immun-
odepression can also be induced by -IFN-based hepatitis C
treatment.5
To the extent of our knowledge, at least 16 Tb cases during
or soon after interferon-based hepatitis C therapy in  non-HIV
patients were reported in 15 articles so far, some of them
describing severe outcomes of tuberculosis reactivation.6–15
The aim of the present study was  to analyze 18 cases of
Tb observed in  reference centers for hepatitis C treatment in
Brazil, country with a  high prevalence of Tb and an  expressive
number of hepatitis C carriers (2–3 million people).3
We  retrospectively analyzed the records of all treated
patients for hepatitis C which were seen monthly during
therapy and identified, based on the signs and symptoms, the
occurrence of Tb cases under various clinical presentations
in patients submitted to -IFN-based therapy for hepatitis C
(pegylated or not).
Patients were evaluated between 2001 and 2012, in  four ref-
erence centers in Brazil (two in Sao Paulo, one in  Rio de Janeiro
and one in Maranhao where the  peak of incidence of tubercu-
losis during this period was 43.7/100,000 in 2001, 93.9/100,000
in  2001 and 47/100,000 in 2002, respectively).16 Cases were
considered related to hepatitis C treatment when diagnosed
during or within six  months after the end of treatment.
Once the cases had been identified, their medical records
were reviewed to obtain epidemiological, clinical, laboratory,
and therapeutic characteristics related to hepatitis C  and Tb
and the data about the decision to  interrupt treatment. This
decision was  made by clinical judgment based on the severity
of the disease.
This study reports secondary data from a main study
approved by the  Ethics Committee for Clinical Research of the
main study center.
We identified 18  cases of Tb in our study, with an incidence
rate of 809 cases/100,000 treated patients.
The majority of patients were male (78%), with a  mean age
of 49 ± 10  years; 15 patients (83%) had significant liver fibrosis,
including six (33%) with cirrhosis; HCV genotype 1  was the
most frequent (78%). The mean time under hepatitis C treat-
ment until the onset of Tb symptoms was 33 ±  15 weeks. The
mean hemoglobin level on Tb diagnosis was 12.1 ±  4.2 g/dL and
the mean of neutrophil counts was 3596 ± 1938 cells/mm3.
Most patients were treated for hepatitis C with double
therapy, including -IFN (pegylated or not) associated with
ribavirin (89%). The treatment was discontinued early in  67%
of cases because of Tb onset. In an intention to  treat approach,
only six patients (33%) achieved sustained virological response
(SVR), while five relapsed (RR), and the remaining were non-
responders (NR).
At least nine patients (50%) had other risk factors for
Tb development (diabetes mellitus, chronic kidney disease,
tobacco smoking, or alcohol intake). Both Diabetes mellitus and
chronic kidney disease coexisted in 17% of Tb cases. Cirrho-
sis was present in 33% of cases. The most frequent clinical
presentation was pulmonary Tb, in 50% of cases, with half of
patients developing extra-pulmonary Tb. Only one of cirrhotic
patients had extra-pulmonary Tb (pleural effusion) concomi-
tantly to pulmonary disease.
Symptoms and signs of Tb usually appeared during the
third and fourth trimesters of treatment (83% of cases). Three
patients presented Tb after concluding -IFN therapy (two
after three and one after six months of the end of treatment).
Details of treatment for hepatitis C and Tb are shown in
Table 1 and clinical presentation of Tb in  Table 2.  Nine patients
were treated with the association of rifampicin, isoniazid
and pyrazinamide, adopted in Brazil until 2009 for Tb treat-
ment. From 2010 on, the drug regimen containing rifampicin,
isoniazid, pyrazinamide, and ethambutol was adopted, what
explains its predominance in  the four cases identified between
2010 and 2012.
The 18  Tb cases reported in this study rise the possibility
of a higher risk for infection in  patients under -IFN-based
therapy for  hepatitis C.
b  r a z  j i  n f e c t d  i  s  .  2  0 1  6;2 0(2):205–209 207
Table 1 – Clinical/epidemiological characteristics of patients who  developed tuberculosis during or soon after hepatitis C
treatment.
Case Gender Age
(years)
Liver
fibrosis
(METAVIR)
Genotype Therapeutic
regimen for
hepatitis C
Outcome of
hepatitis C
Risk factors
for Tba
Drug
regimen
for Tb
Outcome of
Tb
1 Mb 50  2 1 IFNpeg2bc/RBVd SVRe RHZEf,g,h,i Cure  without
sequelae
2 M 59  2 1 IFNpeg2aj/RBV  Death DMk,
former
smoker
RHZE Death
3 Fl 58  2 1 IFNpeg2b/RBV SVR RHZE Cure  with sequelae –
ventriculoperitoneal
shunt
4 M 40  4 3 IFNm/RBV NRn Previous
Pulmonary
Tb, former
DAo
SOEp,q,i Cure  without
sequelae
5 M 52  1 1 IFN NR CKDr,
smoker
S,  Ets, E,  Z Cure  without
sequelae
6 M 66  4 1 IFNpeg2a/RBV NR RHZ/SOE Cure  without
sequelae
7 F 50  3 1 IFNpeg2b/RBV RRt RHZ/SOE Cure  without
sequelae
8 M 65  4 1 IFNpeg2a/RBV SVR SOE Cure  without
sequelae
9 F 52  1 1 IFNpeg2a/RBV RR RHZ Cure  without
sequelae
10 M 44  4 3 IFNpeg2b/RBV RR Alcohol
intake
RHZ Cure  without
sequelae
11 M 52  2 3 IFN/RBV NR DM RHZ Cure  without
sequelae
12 M 28  1 1 IFN alone RR CKD RHZE Cure  without
sequelae
13 M 40  2 1 IFNpeg2a alone RR CKD RHZ Cure  without
sequelae
14 F 55  4 1 IFN/RBV NR DM RHZ/SOE Cure  without
sequelae
15 M 53  4 1 IFN/RBV SVR RHE Cure  without
sequelae
16 M 41  2 1 IFNpeg2b/RBV NR AIu,  former
DA
RHZE Cure  without
sequelae
17 M 32  2 3 IFNpeg2b/RBV SVR RHZ Cure  without
sequelae
18 M 47  2 1 IFNpeg2a/RBV SVR RHZ Cure  without
sequelae
a Tuberculosis.
b Male.
c Pegylated -interferon 2b.
d Ribavirin.
e Sustained virological response.
f Rifampicin.
g Isoniazid.
h Pyrazinamide.
i Ethambutol.
j Pegylated -interferon 2a.
k Diabetes mellitus.
l Female.
m Standard -interferon.
n Non-responder.
o Drug addict.
p Streptomycin.
q Ofloxacin.
r Chronic kidney disease.
s Ethionamide.
t Response and  relapse.
u Alcohol intake.
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Table 2 – Clinical aspects and diagnostic methods of tuberculosis cases.
Case Symptoms and signs Damaged organs Diagnostic methods
1 Fever, axillary lymphadenopathy,
asthenia, myalgia
Lymph node Lymph node biopsy
2 Fever, diarrhea, asthenia, night sweats,
nausea, gait disorder
Disseminated Bone marrow biopsy
3 Arthralgia, irritability, transient cognitive
deficit
Central nervous system Cerebrospinal fluid examination
4 Fever, cough, chills, bronchospasm Lungs Chest radiography, positive sputum
smear microscopy
5 Fever, cough Lymph node Lymph node biopsy
6 Fever, cough, fatigue, weight loss, anemia,
leukopenia, thrombocytopenia,
hemoptysis
Lungs  Symptoms and positive tuberculin
skin test
7 Fever, cough, asthenia, anorexia, myalgia,
arthralgia, weight loss, anemia,
leukopenia
Lungs  Positive sputum smear microscopy
8 Cough, asthenia, anemia, leukopenia Lungs Positive sputum smear microscopy
9 Fever, weight loss,  loss of  appetite,
asthenia, night sweats, chest pain,
anemia, leukopenia
Lungs Chest radiography and CTa
10 Fever, cough, weight loss, dyspnea, chest
pain
Pleura and lungs Pleural fluid examination, Chest CT
11 Fever, cough, weight loss Lungs Chest radiography
12 Thoracolumbar pain Spine Spine CT –  Pott’s disease
13 Ascites, weight loss Peritoneum Ascites fluid examination
14 Fever, cough Lungs Chest radiography
15 Left wrist pain Bone/joint Histopathology
16 Night sweats Lungs Positive sputum smear microscopy
17 Cough Lungs and relapse in lymph
node
Positive  sputum smear microscopy
18 Fever, cough, chest pain Pleura and lungs Chest radiography, pleural  fluid
examination
a Computerized tomography.
In a population-based study conducted in Taiwan, an
endemic Tb area, Lin et al., 2014 studied the incidence rates
of active tuberculosis in HCV-infected patients with (n = 621)
or without (n = 2460) interferon-based therapy (IBT). They
observed a non statistically significant increased hazard of
active Tb in HCV infected patients on IBT in one-year follow-
up.17 Moreover, they mention that the investigators had no
access to other important Tb risk factors, detailed laboratory
results, and medication records. They also consider that some
patients could have died before being registered in the Health
Insurance Research Database due to Tb infection or taking
medications for that condition, underestimating the  number
of cases. The magnitude of 809 cases/100,000 treated patients
is more  impressive when the data are compared to  the inci-
dence of Tb cases in the Brazilian population in 2013 (35.4
cases/100,000 inhabitants). Other groups, traditionally a  pri-
ority for Tb control, such as  the indigenous people, have a
lower incidence (94.5 cases/100,000 inhabitants) when com-
pared to our report.1 On the other hand, comparable incidence
rates had been described in renal transplant patients: 803
cases/100,000 patients.18
Most patients were male  within the age group of
higher prevalence of Tb in Brazil.1 Diabetes mellitus and
chronic kidney disease coexisted in less than 20%  of cases,
comorbidities widely known to increase the  risk of active
tuberculosis.19 Cirrhosis, also blamed as  a risk factor for Tb,20
was  present in one third of cases. Half of the cases were extra-
pulmonary tuberculosis, more  compatible with a situation
of immunosuppression, since in non-immunosuppressed
subjects only 15–20% of extra-pulmonary forms are
expected.21
We  observed a  high discontinuation rate of IBT due to the
onset of Tb; one third of patients achieved SVR. On case two,
the acute onset of Tb symptoms and severe and fatal outcome
of the disease in  less than 60 days, bring the possibility of bac-
teremia and sepsis caused by M.  tuberculosis in  an early phase
of infection.15
On the previous case reports the authors discussed many
mechanisms of association between hepatitis C treatment
and Tb reactivation. They suggested that IFN can induce an
impairment of the early immune response against M. tuber-
culosis,  specifically observed on severe cases, besides the  role
of leukopenia, neutropenia, a lowering on T-CD4+ lymphocyte
population and abnormalities on chemotaxis and phagocytic
functions of macrophages5,8,10,11,15.
We  would like to emphasize that many studies had already
showed that -  and -IFN inhibit type I immune response
which is characterized by lL-12, -IFN and TNF- production,
cytokines that restrain M.  tuberculosis. This inhibition could
lead to LTBI reactivation,22 as  occurred on most cases reported
here, including the three cases in  which Tb appeared after
stopping hepatitis C treatment. We  consider that there was a
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residual immune effect of -IFN that can last until 16 weeks
after the last dose administered.
In summary, considering the evidences of -IFN interfer-
ence over the constrainment mechanisms of M.  tuberculosis,
the immune impairment of cirrhotic patients, the increase
of Tb case reports during hepatitis C treatment, as  in this
expressive retrospective study, with atypical and severe pre-
sentations, and the negative impact on SVR, we  think that
these are strong arguments for LTBI screening by tuberculin
skin test and/or by interferon gamma  releasing assays, before
starting -IFN-based therapy. This is even more  important
in countries with high Tb incidence and in  more  susceptible
populations in which epidemiological determinants of both
diseases can coexist and interact. In these medium or low
income countries the use of -IFN-based therapy will still per-
sist for some time before it is  possible to extend the use of
direct-acting antivirals (DAA) for hepatitis C. DAA should be
considered if a patient tests positive for LTBI. Furthermore,
even in the direct active antivirals era,  the inclusion of patients
in the treatment of hepatitis C is an opportunity for LTBI
screening.
Conflicts  of  interest
The authors declare no conflicts of interest.
r  e f  e  r e  n  c  e  s
1. Brasil. Ministério da Saúde. Secretaria de  Vigilância em
Saúde. Boletim Epidemiológico. O controle da tuberculose no
Brasil: avanc¸os, inovac¸ões e desafios; 2014.
2. Brasil. Ministério da Saúde. Secretaria de  Vigilância em
Saúde. Departamento de vigilância Epidemiológica. Manual
de Recomendac¸ões para o controle da tuberculose no
Brasil/Ministério da Saúde, Secretaria de  Vigilância em Saúde.
Brasília: Departamento de  vigilância Epidemiológica; 2011.
3. Brasil. Ministério da Saúde. Secretaria de  Vigilância em
Saúde. Departamento de DST Aids e Hepatites Virais.
Protocolo clínico e Diretrizes Terapêuticas para Hepatite C e
Coinfecc¸ões/Ministério da Saúde, Secretaria de vigilância em
Saúde, Departamento de DST, Aids e Hepatites Virais. Brasília:
Ministério da  Saúde; 2015.
4. Wu P-H, Lin Y-T,  Hsieh K-P, Chuang H-Y, Sheu C-C.  Hepatitis C
virus infection is associated with an  increased risk of active
tuberculosis disease: a nationwide population-based study.
Medicine. 2015;94(33):e1328.
5. Puoti M, Babudieri S, Rezza G,  et al. Use of pegylated
interferons is associated with an increased incidence of
infections during combination treatment of chronic hepatitis
C:  a side effect of pegylation? Antivir Ther. 2004;9(4):627–30.
6. Ferreira CN,  Barjas ER, Correia LA, et al. Generalized
peripheral lymphadenopathy in a patient treated for chronic
HCV infection. Nat Clin Pract Gastroenterol Hepatol.
2008;5(8):469–74.
7. Tsai M-C, Lin M-C, Hung C-H. Successful antiviral
antituberculosis treatment with pegylated interferon-alfa
and ribavirin in a chronic hepatitis C patient with
pulmonary tuberculosis. J  Formos Med Assoc. 2009;108(9):
746–50.
8. Belkahla N, Kchir H, Maamouri N, et al. Reactivation of
tuberculosis during dual therapy with pegylated interferon
and ribavirin for chronic hepatitis C.  Rev Med  Intern.
2010;31(11):e1–3.
9. Velasco J, González S.  Tuberculous lymphadenitis after
successful treatment of hepatitis C. Enferm Infecc Microb
Clin. 2011;29:8.
10. Babudieri S,  Soddu A, Murino M, et al. Tuberculosis screening
before anti-hepatitis C virus therapy in prisons. Emerg Infect
Dis.  2012;18(4):689–91.
11. Lee S,  Atten MJ, Attar B. Esophageal tuberculosis during
treatment of hepatitis C.  Clin Gastroenterol Hepatol.
2013;11(12):A27.
12. Saitou Y, Hatazi O,  Aonuma H, Ogura S,  Yamamoto N,
Kobayashi T. Pulmonary tuberculoma in a  patient with
chronic hepatitis C: a clinical pitfall in the treatment strategy.
Intern Med (Tokyo, Japan). 2014;53(15):1669–74.
13. Rodrigues-Martín L, Linares Torres P, Aparicio Cabezudo M,
et al. Reactivation of pulmonary tuberculosis during
treatment  with triple therapy for hepatitis C. Gastroenterol
Hepatol. 2015.
14. Fukuba R, Kawaratani H, Kubo T, et al. Tuberculous peritonitis
during  pegylated interferon plus ribavirin combination
therapy in a  patient with chronic hepatitis C. Nippon
Shokakibyo Gakkai Zasshi. 2014;111(12):2337–45.
15. Hametner S, Monticelli F,  Kern JM, Schofl R, Ziachehabi A,
Maieron A.  Tuberculous sepsis during antiviral HCV triple
therapy. J  Hepatol. 2013;59(3):637–8.
16. Brasil. Ministério da Saúde. Secretaria de Vigilância em
Saúde. Programa Nacional de Controle da Tuberculose. Série
histórica da taxa de incidência de  tuberculose. Brasil, regiões
e  unidades federadas de  residência por ano de diagnóstico
(1990  a 2014); 2015. Available from: http://portalsaude.
saude.gov.br/images/pdf/2015/setembro/24/taxa-incid–ncia-
tuberculose-1999-2014-base-JUN-2015.pdf [cited 30.11.15]
[Internet].
17.  Lin S, Chen T, Lu P, et al. Incidence rates of tuberculosis in
chronic hepatitis C infected patients with or without
interferon based therapy: a population-based cohort study in
Taiwan. BMC Infect Dis. 2014;14(1):705.
18. Marques ID, Azevedo LS, Pierrotti LC, et al. Clinical features
and outcomes of tuberculosis in kidney transplant recipients
in Brazil: a  report of the last decade. Clin Transpl.
2013;27(2):E169–76.
19. Santin Cerezales M, Navas Elorza E. Tuberculosis in special
populations. Enferm Infecc Microb Clin. 2011;29 Suppl. 1:
20–5.
20. Lin YT, Wu  PH, Lin CY, et al. Cirrhosis as  a  risk factor for
tuberculosis infection – a  nationwide longitudinal study in
Taiwan. Am J  Epidemiol. 2014;180(1):8.
21. Sharma SK, Mohan A.  Extrapulmonary tuberculosis. Indian J
Med  Res. 2004;120(4):316–53.
22. de  Paus RA, van Wengen A, Schmidt I, et al. Inhibition of the
type I  immune responses of human monocytes by IFN-alpha
and IFN-beta. Cytokine. 2013;61(2):645–55.
